Co-nanoencapsulated meloxicam and curcumin improves cognitive impairment induced by amyloid-beta through modulation of cyclooxygenase-2 in mice
| Autor: | Renata Bem dos Santos, Anne Suély Pinto Savall, Simone Pinton, Cristiane Luchese, Edina da Luz Abreu, Caroline Brandão Quines, Marina Costa Monteiro Guedes, Maria Eduarda Ziani Gutierrez, Kelly Ayumi Nakama, Sandra Elisa Haas, Daiana Silva Ávila |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Amyloid beta Inflammation Pharmacology Neuroprotection lcsh:RC346-429 memory 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Developmental Neuroscience Downregulation and upregulation alzheimer’s disease curcumin cyclooxygenase-2 lipid core nanocapsules meloxicam rats inflammation Medicine lcsh:Neurology. Diseases of the nervous system biology business.industry Alzheimer's disease Pathophysiology Meloxicam 030104 developmental biology chemistry Curcumin biology.protein Cyclooxygenase medicine.symptom business 030217 neurology & neurosurgery medicine.drug Research Article |
| Zdroj: | Neural Regeneration Research, Vol 16, Iss 4, Pp 783-789 (2021) Neural Regeneration Research |
| ISSN: | 1673-5374 |
| Popis: | Alzheimer's disease (AD) is a progressive brain disorder and complex mechanisms are involved in the physiopathology of AD. However, there is data suggesting that inflammation plays a role in its development and progression. Indeed, some non-steroidal anti-inflammatory drugs, such as meloxicam, which act by inhibiting cyclooxygenase-2 (COX-2) have been used as neuroprotective agents in different neurodegenerative disease models. The purpose of this study was to investigate the effects of co-nanoencapsulated curcumin and meloxicam in lipid core nanocapsules (LCN) on cognitive impairment induced by amyloid-beta peptide injection in mice. LCN were prepared by the nanoprecipitation method. Male Swiss mice received a single intracerebroventricular injection of amyloid-beta peptide aggregates (fragment 25-35, 3 nmol/3 μL) or vehicle and were subsequently treated with curcumin-loaded LCN (10 mg/kg) or meloxicam-loaded LCN (5 mg/kg) or meloxicam + curcumin-co-loaded LCN (5 and 10 mg/kg, respectively). Treatments were given on alternate days for 12 days (i.e., six doses, once every 48 hours, by intragastric gavage). Our data showed that amyloid-beta peptide infusion caused long-term memory deficits in the inhibitory avoidance and object recognition tests in mice. In the inhibitory avoidance test, both meloxicam and curcumin formulations (oil or co-loaded LCN) improved amyloid-beta-induced memory impairment in mice. However, only meloxicam and curcumin-co-loaded LCN attenuated non-aversive memory impairment in the object recognition test. Moreover, the beneficial effects of meloxicam and curcumin-co-loaded LCN could be explained by the anti-inflammatory properties of these drugs through cortical COX-2 downregulation. Our study suggests that the neuroprotective potential of meloxicam and curcumin co-nanoencapsulation is associated with cortical COX-2 modulation. This study was approved by the Committee on Care and Use of Experimental Animal Resources, the Federal University of Pampa, Brazil (approval No. 02-2015) on April 16, 2015. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|